[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634159":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":77,"collaborators":30,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":30,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":30,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":65,"whyStopped":30,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Sarepta Therapeutics, Inc.","INDUSTRY",[8,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: SRP-1005 Dose 1","EXPERIMENTAL","Participants will receive SRP-1005 or placebo.",[13,14],"Drug: SRP-1005","Drug: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort 2: SRP-1005 Dose 2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Cohort 3: SRP-1005 Dose 3",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Cohort 4: SRP-1005 Dose 4",[13,14],[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","SRP-1005","Subcutaneous injection",[9,16,19,22],null,{"type":26,"name":32,"description":28,"armGroupLabels":33,"otherNames":30},"Placebo",[9,16,19,22],[35],{"name":36,"affiliation":5,"role":37},"Medical Director","STUDY_DIRECTOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":30,"email":43},"Sarepta Therapeutics Inc., For Clinical Trial Information, Select Option 4","CONTACT","1-888-SAREPTA (1-888-727-3782)","SareptAlly@sarepta.com",[45,63],{"facility":46,"status":47,"city":48,"state":30,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Pacific Clinical Research Network - Auckland (PCRN Auckland)","NOT_YET_RECRUITING","Auckland","622","New Zealand","NZ",{"type":53,"coordinates":54},"Point",[55,56],174.76349,-36.84853,{"lat":56,"lon":55},[59,60],{"name":30,"role":41,"phone":30,"phoneExt":30,"email":43},{"name":61,"role":62,"phone":30,"phoneExt":30,"email":30},"Richard Roxburgh, FRACP, PHD","PRINCIPAL_INVESTIGATOR",{"facility":64,"status":65,"city":66,"state":30,"zip":67,"country":50,"countryCode":51,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"New Zealand Brain Research Institute","RECRUITING","Christchurch","8014",{"type":53,"coordinates":69},[70,71],172.63333,-43.53333,{"lat":71,"lon":70},[74,75],{"name":30,"role":41,"phone":30,"phoneExt":30,"email":43},{"name":76,"role":62,"phone":30,"phoneExt":30,"email":30},"Timothy Anderson, MD, FRACP",{"type":78,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100634159","phase-1-a-first-in-human-study-of-the-effects-of-srp-1005-in-participants-with-huntingtons-disease-100634159",false,"NCT07536061","A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease","A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)","Key Inclusion Criteria:\n\n* Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40.\n* Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator as either Stage 2 or Mild Stage 3.\n* Participants who are of childbearing potential, or with partners of childbearing potential, who are sexually active must agree to use a highly effective method of contraception throughout study participation, and for at least 90 days following the end of study.\n\nKey Exclusion Criteria:\n\n* Any condition that would compromise the safety or feasibility of lumbar puncture or magnetic resonance imaging (MRI).\n* Presence of other significant neurological or systemic illnesses.\n* Current, chronic or active human immunodeficiency virus, hepatitis B\u002FC.\n* Recent use of investigational agents or HTT-lowering therapies.\n* Uncontrolled psychiatric illness or substance use disorders.\n* Pregnancy or lactation.\n\nNote: Other inclusion\u002Fexclusion criteria apply.","ALL","21 Years","70 Years",{"count":90,"type":91},32,"ESTIMATED","INTERVENTIONAL",[94],"PHASE1","This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).",[97],"Huntington's Disease",[99,27,100,101],"Huntington's disease","Dose Escalation","First in Human","2026-06-03",{"date":104,"type":105},"2026-06-04","ACTUAL",{"date":107,"type":105},"2026-05-12",{"date":109,"type":91},"2027-11-30",{"name":5,"class":6},2]